Sepsis & infection

Fluid management for sepsis-induced hypotension in patients with advanced chronic kidney disease: a secondary analysis of the crystalloid liberal or vasopressor early resuscitation in sepsis (CLOVERS) trial

Crit CarePublished Secondary analysis of the CLOVERS randomised trial

Primary result · Death from any cause before discharge home by day 90Result — go to the resultHazard ratio 0.5 95% CI 0.29–0.85

Authors' conclusion

In patients with advanced CKD and sepsis-induced hypotension, an early restrictive fluid strategy, prioritizing vasopressor use, was associated with a lower risk of death from any cause before discharge home by day 90 as compared with an early liberal fluid strategy.

Study context

Population
Patients with sepsis-induced hypotension and advanced chronic kidney disease (CKD) (eGFR <30 mL/min/1.73 m² or end-stage renal disease on chronic dialysis)45% on chronic dialysis
Participants
196 patients
Comparison
Early restrictive vs liberal fluid management
  • Restrictiven = 92
  • Liberaln = 104reference
Primary endpoint
Death from any cause before discharge home
Follow-up
Day 90
Methodological detailspost-hoc analysis
  • Post-hoc analysis

Primary result

As reported in the abstract

Death from any cause before discharge home by day 90

Hazard ratio

0.5

95% CI 0.29–0.85

Events by treatment group

Restrictive vs Liberal
HR 0.5 (95% CI 0.29–0.85)

Further findings

OutcomeRestrictiveLiberalMean difference (days) (95% CI)
Vasopressor-free days19.7 ± 10.4 days15.4 ± 12.6 days4.3 (1.0–7.5)
Ventilator-free days · day 2821.0 ± 11.8 days16.5 ± 13.6 days4.5 (0.9–8.1)

Original publication

Fluid management for sepsis-induced hypotension in patients with advanced chronic kidney disease: a secondary analysis of the CLOVERS trial. Crit Care. Published 11 July 2024. doi:10.1186/s13054-024-05019-6

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.